哪里想瘦打哪里！FDA批准Kythera注射药物母公司在即

你才双下巴，你老家都双下巴！所谓美的之心人皆有之。如果说赘肉是每一个愿意具备与众不同身材的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴已是是这些人的人间憎恨了。每一分钟，世界各地都有人为自己的一张大饼脸而感到无常，虽然具备一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的心理素质使其无法承受一个双下巴之重。您可千万别笑，这甚至之前催生出新一个远超过的低价。根据美国表皮外科手术协会的调查学术研究显示，68%的墨西哥人对自己的双下巴表示了“厌倦”之情。而亦然，最近Kythera美国公司向FDA提交了其专门肃清双下巴的保养品麻醉式抗生素ATX-101。这种抗生素完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，已是是不间断减肥。不要以为这种即便如此温柔的抗生素只是一个开玩笑，在FDA其下属的表皮和牙科抗生素局长会的无记名投票中所，专家可是以17：0的超高票数一致赞同其上市。或许是因为这些专家中所也有很多饱受双下巴之苦吧。FDA也将计划于上周的5年初13日之前对其作出新再次决定。如果一切顺利的话，Kythera美国公司计划于上周年初末将该产品上市，分析人士预计这一抗生素的交易额将超过3亿美元之多。随着保养品抗生素低价的越来越增大，Kythera美国公司已是是下了一步好棋。美国公司于当年以8400万美元的定价从其前伙伴拜耳手中所收回了这种抗生素的全部特权。而Kythera美国公司也愿意借以为契机在保养品抗生素低价中所固守拔寨。就在上个年初，Kythera美国公司和Actelion美国公司达成效益2700万美元的合作两国政府，联合开发一种失败过的抗水肿抗生素，而这种抗生素被并不认为有可能开发出新一种用药脱发的抗生素。详实英文报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.